Stocks and Investing
Stocks and Investing
Tue, July 13, 2021
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Charles Duncan Initiated (ATAI) at Buy and Held Target at $45 on, Jul 13th, 2021
Charles Duncan of Cantor Fitzgerald, Initiated "Atai Life Sciences N.V." (ATAI) at Buy and Held Target at $45 on, Jul 13th, 2021.
Charles has made no other calls on ATAI in the last 4 months.
There is 1 other peer that has a rating on ATAI. Out of the 1 peers that are also analyzing ATAI, 0 agree with Charles's Rating of Hold.
This is the rating of the analyst that currently disagrees with Charles
- Nathan Weinstein of "Aegis Capital" Initiated at Strong Buy and Held Target at $26 on, Thursday, July 8th, 2021
Contributing Sources